The Guangdong Medical Products Administration issued three landmark policy documents governing imported Hong Kong and...
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that FXS7553 has initiated a...
Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA: 688176) announced that its independently developed APL‑2501 has received...
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its drug HRS‑4729 has...
CanSino Biologics (HKG: 6185) announced that it has submitted a New Drug Application (NDA) in...
Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that Phase I/II clinical trials are underway for...
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has entered into a strategic collaboration...
Shanghai Ark Biopharmaceutical Co., Ltd. announced that the US Food and Drug Administration (FDA) has...
Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE: 002907) announced that its drug candidate ORIC‑1327 has received...
Yiling Pharmaceutical (SHE: 002603) announced that it has submitted an Investigational New Drug (IND) application...
Pfizer Inc. (NYSE: PFE) and Valneva SE (NASDAQ: VALN) announced that the European Medicines Agency...
Sino Medical Sciences Technology Inc. (SHA: 688108) announced that its independently developed Ghunter Revascularization Device,...
Bristol-Myers Squibb (BMS) (NYSE: BMY) announced that the US Food and Drug Administration (FDA) has...
Xbiome, a China‑based AI‑driven microbiome drug development company, announced a technology collaboration deal with Biogent...
According to the latest announcement from the Center for Drug Evaluation (CDE) of the National...
ACROBiosystems Co., Ltd. (SHE: 301080) and Bailinke Pharmaceutical Technology (Shanghai) Co., Ltd. have entered into...
Celgenyx, Inc. announced today that CG101, its self‑developed off‑the‑shelf immune cell therapy product for the...
China’s National Medical Products Administration (NMPA) has released for public comment the “Implementation Rules for...
TJ Biopharma and Biogen Inc. (NASDAQ: BIIB) announced today that felzartamab for injection (brand name:...
IASO Biotherapeutics, a Chinese cell therapy innovator, announced today that it has completed its acquisition...